Nuveen Asset Management LLC cut its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 39.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,249 shares of the biotechnology company’s stock after selling 10,110 shares during the period. Nuveen Asset Management LLC’s holdings in bluebird bio were worth $1,386,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. First Mercantile Trust Co. increased its position in bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 365 shares during the period. Berkeley Capital Partners LLC acquired a new position in bluebird bio during the first quarter valued at $282,000. Teacher Retirement System of Texas acquired a new position in bluebird bio during the first quarter valued at $291,000. Two Sigma Securities LLC acquired a new position in bluebird bio during the first quarter valued at $304,000. Finally, Smith Asset Management Group LP acquired a new position in bluebird bio during the first quarter valued at $311,000.

Shares of bluebird bio, Inc. (BLUE) opened at 97.30 on Thursday. The company has a 50 day moving average of $102.98 and a 200 day moving average of $87.04. The firm’s market capitalization is $3.98 billion. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.76) by $0.08. The business had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $1.51 million. bluebird bio had a negative return on equity of 35.17% and a negative net margin of 2,402.03%. On average, analysts anticipate that bluebird bio, Inc. will post ($6.70) earnings per share for the current fiscal year.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/07/20/bluebird-bio-inc-blue-shares-sold-by-nuveen-asset-management-llc.html.

Several research firms have weighed in on BLUE. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald set a $39.00 target price on shares of bluebird bio and gave the company a “sell” rating in a report on Saturday, June 24th. Morgan Stanley restated an “equal weight” rating and set a $103.00 target price (down from $105.00) on shares of bluebird bio in a report on Monday, July 10th. BidaskClub downgraded shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a report on Friday, June 30th. Finally, Cowen and Company restated an “outperform” rating on shares of bluebird bio in a report on Friday, June 9th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. bluebird bio currently has a consensus rating of “Buy” and an average price target of $100.02.

In related news, Director Daniel Lynch sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $90.01, for a total value of $90,010.00. Following the completion of the sale, the director now owns 2,400 shares of the company’s stock, valued at approximately $216,024. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jason Cole sold 17,245 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $100.22, for a total value of $1,728,293.90. Following the completion of the sale, the insider now directly owns 30,871 shares of the company’s stock, valued at approximately $3,093,891.62. The disclosure for this sale can be found here. In the last three months, insiders sold 76,245 shares of company stock valued at $7,924,508. 3.90% of the stock is currently owned by company insiders.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.